Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, fir-b/fox, in young-elderly metastatic colorectal cancer Patients

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Bruera, Gemma ^a   Cannita, Katia ^a   Giordano, Aldo Victor ^b   Vicentini, Roberto ^b   Ficorella, Corrado ^a   Ricevuto, Enrico ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; RALTITREXED; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; DRUG DERIVATIVE; FOLINIC ACID; KRAS PROTEIN, HUMAN; METHOTREXATE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENOTYPE; GINGIVITIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RHINITIS; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; WHOLE BODY RADIATION; CLINICAL TRIAL; COLORECTAL TUMOR; DEMOGRAPHY; DOSE RESPONSE; GENETICS; KAPLAN MEIER METHOD; METASTASIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC);

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; DEMOGRAPHY; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; METHOTREXATE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84888615395     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/143273     Document Type: Article

References (43)

1. Bruera G., Santomaggio A., Cannita K., Baldi P. L., Tudini M., De Galitiis F., Mancini M., Marchetti P., Antonucci A., Ficorella C., Ricevuto E., "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010 10, article 567 2-s2.0-77957916099 10.1186/1471-2407-10-567
2. Bruera G., Ricevuto E., Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52. Expert Opinion on Bioogical Theraphy 2011 11 6 821 824 10.1517/14712598.2011.582462
3. Bruera G., Cannita K., Giuliante F., Lanfiuti Baldi P., Vicentini R., Marchetti P., Nuzzo G., Antonucci A., Ficorella C., Ricevuto E., Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clinical Colorectal Cancer 2012 11 2 119 126
4. Ficorella C., Bruera G., Cannita K., Porzio G., Lanfiuti Baldi P., Tinari N., Natoli C., Ricevuto E., Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. Clinical Colorectal Cancer 2012 11 4 229 237
5. Bruera G., Cannita K., Di Giacomo D., Lamy A., Troncone G., Dal Mas A., Coletti G., Frébourg T., Sabourin J. C., Tosi M., Ficorella C., Ricevuto E., Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Medicine 2012 10 1, article 135
6. Bruera G., Cannita K., Giordano A. V., Vicentini R., Ficorella C., Ricevuto E., Differential prognosis of metastatic colorectal cancer patients post-progression to first line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second line treatment and KRAS genotype. International Journal of Oncology. In press
7. Masi G., Vasile E., Loupakis F., Cupini S., Fornaro L., Baldi G., Salvatore L., Cremolini C., Stasi I., Brunetti I., Fabbri M. A., Puglisi M., Trenta P., Granetto C., Chiara S., Fioretto L., Allegrini G., Crin L., Andreuccetti M., Falcone A., Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. Journal of the National Cancer Institute 2011 103 1 21 30 2-s2.0-78651297593 10.1093/jnci/djq456
8. Schmoll H. J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Nordlinger B., van de Velde C. J., Balmana J., Regula J., Nagtegaal I. D., Beets-Tan R. G., Arnold D., Ciardiello F., Hoff P., Kerr D., Köhne C. H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J. Y., El Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos I., Turhal S., Cervantes A., ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology 2012 23 2479 2516
9. Pallis A. G., Papamichael D., Audisio R., Peeters M., Folprecht G., Lacombe D., Van Cutsem E., EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients. Cancer Treatment Reviews 2010 36 1 83 90 2-s2.0-75049085080 10.1016/j.ctrv.2009.10.008
10. Papamichael D., Audisio R., Horiot J.-C., Glimelius B., Sastre J., Mitry E., Van Cutsem E., Gosney M., Köhne C.-H., Aapro M., Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Annals of Oncology 2009 20 1 5 16 2-s2.0-58949089717 10.1093/annonc/mdn532
11. Audisio R. A., Papamichael D., Treatment of colorectal cancer in older patients. Nature Reviews Gastroenterology & Hepatology 2012 9 12 716 725
12. Extermann M., Overcash J., Lyman G. H., Parr J., Balducci L., Comorbidity and functional status are independent in older cancer patients. Journal of Clinical Oncology 1998 16 4 1582 1587 2-s2.0-0031901577 (Pubitemid 28175784)
13. Folprecht G., Cunningham D., Ross P., Glimelius B., Di Costanzo F., Wils J., Scheithauer W., Rougier P., Aranda E., Hecker H., Köhne C.-H., Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Annals of Oncology 2004 15 9 1330 1338 2-s2.0-4644288273 10.1093/annonc/mdh344 (Pubitemid 39302467)
14. Popescu R. A., Norman A., Ross P. J., Parikh B., Cunningham D., Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. Journal of Clinical Oncology 1999 17 8 2412 2418 2-s2.0-0032792959 (Pubitemid 29368240)
15. Chiara S., Nobile M. T., Vincenti M., Lionetto R., Gozza A., Barzacchi M. C., Sanguineti O., Repetto L., Rosso R., Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemotherapy and Pharmacology 1998 42 4 336 340 2-s2.0-0031823713 10.1007/s002800050826 (Pubitemid 28393852)
16. Folprecht G., Seymour M. T., Saltz L., Douillard J.-Y., Hecker H., Stephens R. J., Maughan T. S., Van Cutsem E., Rougier P., Mitry E., Schubert U., Köhne C.-H., Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology 2008 26 9 1443 1451 2-s2.0-41149180580 10.1200/JCO.2007.14.0509
17. Mitry E., Douillard J.-Y., Van Cutsem E., Cunningham D., Magherini E., Mery-Mignard D., Awad L., Rougier P., Predictive factors of survival in patients with advanced colorectal cancer: an indiviual data analysis of 602 patients included in irinotecan phase III trials. Annals of Oncology 2004 15 7 1013 1017 2-s2.0-4143089333 10.1093/annonc/mdh267 (Pubitemid 39089776)
18. Goldberg R. M., Tabah-Fisch I., Bleiberg H., De Gramont A., Tournigand C., Andre T., Rothenberg M. L., Green E., Sargent D. J., Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. Journal of Clinical Oncology 2006 24 25 4085 4091 2-s2.0-33748669385 10.1200/JCO.2006.06.9039 (Pubitemid 46622283)
19. Figer A., Perez-Staub N., Carola E., Tournigand C., Lledo G., Flesch M., Barcelo R., Cervantes A., André T., Colin P., Louvet C., De Gramont A., FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007 110 12 2666 2671 2-s2.0-37049022436 10.1002/cncr.23091 (Pubitemid 350250335)
20. Seymour M. T., Thompson L. C., Wasan H. S., Middleton G., Brewster A. E., Shepherd S. F., O'Mahony M. S., Maughan T. S., Parmar M., Langley R. E., Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. The Lancet 2011 377 9779 1749 1759 2-s2.0-79956346875 10.1016/S0140-6736(11)60399-1
21. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004 350 23 2335 2342 2-s2.0-2542561964 10.1056/NEJMoa032691 (Pubitemid 38702844)
22. Kabbinavar F. F., Hurwitz H. I., Yi J., Sarkar S., Rosen O., Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. Journal of Clinical Oncology 2009 27 2 199 205 2-s2.0-58249088835 10.1200/JCO.2008.17.7931
23. Cassidy J., Saltz L. B., Giantonio B. J., Kabbinavar F. F., Hurwitz H. I., Rohr U.-P., Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Journal of Cancer Research and Clinical Oncology 2010 136 5 737 743 2-s2.0-77950494294 10.1007/s00432-009-0712-3
24. Kozloff M. F., Berlin J., Flynn P. J., Kabbinavar F., Ashby M., Dong W., Sing A. P., Grothey A., Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010 78 5-6 329 339 2-s2.0-77956072936 10.1159/000320222
25. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., Dibartolomeo M., Mazier M.-A., Canon J.-L., Georgoulias V., Peeters M., Bridgewater J., Cunningham D., Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology 2009 20 11 1842 1847 2-s2.0-66149120036 10.1093/annonc/mdp233
26. Meyerhardt J. A., Jackson McCleary N., Niedzwiecki D., Hollis D., Venook A., Mayer R., Goldberg R., Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB, 80203. Journal of Clinical Oncology 2009 27 15s (supplement, abstr 4038)
27. Douillard J.-Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., Humblet Y., Bodoky G., Cunningham D., Jassem J., Rivera F., Kocákova I., Ruff P., Błasińska-Morawiec M., Šmakal M., Canon J.-L., Rother M., Oliner K. S., Wolf M., Gansert J., Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of Clinical Oncology 2010 28 31 4697 4705 2-s2.0-78149250536 10.1200/JCO.2009.27.4860
28. Souglakos J., Androulakis N., Syrigos K., Polyzos A., Ziras N., Athanasiadis A., Kakolyris S., Tsousis S., Kouroussis C., Vamvakas L., Kalykaki A., Samonis G., Mavroudis D., Georgoulias V., FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). British Journal of Cancer 2006 94 6 798 805 2-s2.0-33645309877 10.1038/sj.bjc.6603011
29. Vamvakas L., Athanasiadis A., Karampeazis A., Kakolyris S., Polyzos A., Kouroussis C., Ziras N., Kalbakis K., Georgoulias V., Souglakos J., Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Critical Reviews in Oncology/Hematology 2010 76 1 61 70 2-s2.0-77956613335 10.1016/j.critrevonc. 2009.08.003
30. Ficorella C., Ricevuto E., Morelli M. F., Morese R., Cannita K., Cianci G., Porzio G., Di Rocco Z. C., De Galitiis F., De Tursi M., Tinari N., Iacobelli S., Marchetti P., Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: a dose-finding study. Oncology Reports 2006 15 5 1345 1350 2-s2.0-33744989481
31. Morelli M. F., Santomaggio A., Ricevuto E., Cannita K., De Galitiis F., Tudini M., Bruera G., Mancini M., Pelliccione M., Calista F., Guglielmi F., Martella F., Lanfiuti Baldi P., Porzio G., Russo A., Gebbia N., Iacobelli S., Marchetti P., Ficorella C., Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncology Reports 2010 23 6 1635 1640 2-s2.0-77951706637 10.3892/or-00000805
32. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M. P., Bastit L., Killian A., Sesboüé R., Tuech J. J., Queuniet A. M., Paillot B., Sabourin J. C., Michot F., Michel P., Frebourg T., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer 2007 96 8 1166 1169 2-s2.0-34247278727 10.1038/sj.bjc.6603685 (Pubitemid 46625066)
33. Lamy A., Blanchard F., Le Pessot F., Sesboüé R., Di Fiore F., Bossut J., Fiant E., Frébourg T., Sabourin J.-C., Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Modern Pathology 2011 24 8 1090 1100 2-s2.0-79961025560 10.1038/modpathol.2011.60
34. Mantel N., Chi-square tests with one degree of freedom: extensions of the Mendel-Haenszel procedure. Journal of the American Statistical Association 1963 58 690 700
35. Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A. T., Christian M. C., Gwyther S. G., New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000 92 3 205 216 2-s2.0-0034594628 (Pubitemid 30099779)
36. Kaplan E. L., Meier P., Nonparametric estimation of incomplete observations. Journal of the American Statistical Association 1958 53 457 481
37. Peto R., Peto J., Asymptomatically efficient rank invariant test procedures. Journal of the Royal Statistical Society A 1972 135 185 206
38. Masi G., Loupakis F., Salvatore L., Fornaro L., Cremolini C., Cupini S., Ciarlo A., Del Monte F., Cortesi E., Amoroso D., Granetto C., Fontanini G., Sensi E., Lupi C., Andreuccetti M., Falcone A., Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. The Lancet Oncology 2010 11 9 845 852 2-s2.0-77956189945 10.1016/S1470-2045(10)70175-3
39. Garufi C., Torsello A., Tumolo S., Ettorre G. M., Zeuli M., Campanella C., Vennarecci G., Mottolese M., Sperduti I., Cognetti F., Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. British Journal of Cancer 2010 103 10 1542 1547 2-s2.0-78149469673 10.1038/sj.bjc. 6605940
40. Sargent D. J., Köhne C. H., Sanoff H. K., Bot B. M., Seymour M. T., De Gramont A., Porschen R., Saltz L. B., Rougier P., Tournigand C., Douillard J.-Y., Stephens R. J., Grothey A., Goldberg R. M., Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. Journal of Clinical Oncology 2009 27 12 1948 1955 2-s2.0-65349173894 10.1200/JCO.2008.20.2879
41. Adam R., Frilling A., Elias D., Laurent C., Ramos E., Capussotti L., Poston G. J., Wicherts D. A., De Haas R. J., Liver resection of colorectal metastases in elderly patients. British Journal of Surgery 2010 97 3 366 376 2-s2.0-76649122170 10.1002/bjs.6889
42. Figueras J., Ramos E., López-Ben S., Torras J., Albiol M., Llado L., González H. D., Rafecas A., Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clinical and Translational Oncology 2007 9 6 392 400 2-s2.0-34848818021 10.1007/s12094-007-0072-x
43. Scappaticci F. A., Skillings J. R., Holden S. N., Gerber H.-P., Miller K., Kabbinavar F., Bergsland E., Ngai J., Holmgren E., Wang J., Hurwitz H., Arterial thromboembolic events and patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute 2007 99 1232 1239 2-s2.0-49749150551 10.1093/jnci/djn126 (Pubitemid 47299901)